Compare Manhattan Associates Inc (MANH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Novo Nordisk A/S — how do they compare? Manhattan Associates Inc trades at $162.1 (market cap $9.66B), while Novo Nordisk A/S trades at $49.8 (market cap $221.80B). The key difference: Novo Nordisk A/S is far larger — about 23× Manhattan Associates Inc's market cap, and Novo Nordisk A/S pays a 3.58% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| MANH | NVO | |
|---|---|---|
Market Cap | $9.66B | $221.80B |
Sector | Technology | Health |
52-Week High | $227.94 | $71.70 |
52-Week Low | $120.88 | $35.29 |
Enterprise Value | $9.49B | $240.76B |
Dividend Yield | — | 3.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manhattan Associates (MANH) trades at $163.19, up 0.04% with strong technical momentum and bullish moving average signals. The company demonstrates robust profitability with 56% gross margins and 19.68% net income margin, though valuations appear elevated with a P/E of 45.75. Recent quarterly earnings consistently beat expectations, supporting the stock's upward trajectory. However, multiple news outlets report ongoing investigations into fiduciary duties by company directors.
MANH presents a mixed outlook with strong fundamental performance offset by high valuation and legal concerns. The 18% upside to consensus price target of $192.80 suggests analyst optimism, but investors face risks from the ongoing investigations and potential market volatility. The stock's technical strength supports near-term bullish sentiment despite overbought RSI conditions.
NVO trades at $50.32, down 2.25% over 24 hours, with a bullish technical signal from moving averages and ADX indicators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $309.06B in 2025, and net income margin remains robust at 37.2%. Recent approvals for Wegovy in the EU and India highlight expansion momentum, though competition in GLP-1 therapies is intensifying.
Outlook remains positive given earnings strength and market leadership in weight-loss drugs, but risks include competitive pressure from new entrants and regulatory hurdles. Analysts are predominantly bullish with 57.9% buy ratings, supporting a favorable investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
